The Prognostic Value of Residual Disease in Ovarian Cancer Authors: Sabrina Serani & Amir Jazaeri, MD Fact checked by: Jason M. Broderick August 22, 2025 Key Takeaways SLL and ctDNA are effective in detecting MRD in ovarian cancer, surpassing conventional methods like CA 125 and CT scans. SLL provides access to MRD tissue, offering insights into chemoresistance and potential therapeutic targets. CtDNA is a promising early surrogate endpoint in clinical trials, allowing earlier assessment of treatment efficacy. Identifying high-risk patients through these methods enables earlier intervention with innovative and investigational therapies. Read More at Targeted Oncology...

Continue reading

Study Reveals Missed Opportunities for Surgical Prevention of Ovarian Cancer Author: Jason M. Broderick Fact checked by: Sabrina Serani August 15, 2025 Key Takeaways Concurrent salpingectomy during unrelated surgeries could prevent 25% of HGSC cases, highlighting missed opportunities in 23.7% of patients. Missed genetic testing and risk-reducing surgery occurred in 43.2% of women with a first-degree relative affected by HGSC. The study suggests a risk-assessment algorithm to prioritize salpingectomy and individualized counseling for patients with different risk profiles. Read More at Targeted Oncology...

Continue reading

Missed Opportunities to Prevent Ovarian Cancer During Unrelated Surgeries by Charles Bankhead, Senior Editor, MedPage Today August 14, 2025 • 4 min read Salpingectomy often omitted during surgery for permanent contraception, other procedures Key Takeaways Genetic susceptibility accounts for 20% of ovarian cancer risk, and risk-reducing bilateral salpingectomy remains the gold standard for prevention. In this study, about 24% of patients with high-grade serous ovarian cancer had missed opportunities for risk-reducing surgery before cancer diagnosis. Among the women with a first-degree family history of ovarian cancer, 43.2% had mutations that increased susceptibility to ovarian cancer. Read More at MedPage Today...

Continue reading

Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission August 04, 2025 Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies. Author: Russ Conroy Fact checked by: Roman Fabbricatore Read More at CancerNetwork...

Continue reading

I had one simple surgery to lower my risk of the deadliest cancer for women. Here’s why you probably don’t know about it—but should June 16, 2025 I woke up from surgery groggy, with three minuscule incisions in my abdomen and huge peace of mind. I’d just had my fallopian tubes laparoscopically removed, as it’s the best—and possibly only—defense against ovarian cancer, which, though rare, is the most lethal gynecological cancer there is. Read More at Fortune Well...

Continue reading

New collaborative effort aims to cure ALK-positive lung cancer December 6, 2024 Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who have never smoked, including those aged between 20 and 50. Upon diagnosis, 80% of individuals already have stage 4 metastatic cancer, spread beyond the lungs to other parts of the body. Despite initially effective ALK inhibitor treatments, the cancer recurs in most patients, and there are about 70,000 people living with ALK+ lung cancer in the United States. Read......

Continue reading

Radical Collaboration: Reimagining Cancer Team Science By: Jesse Boehm and Tyler Jacks Here, we define a future of cancer team science adopting “radical collaboration”—in which six “Hallmarks of Cancer Collaboration” are utilized to propel cancer teams to reach new levels of productivity and impact in the modern era. This commentary establishes a playbook for cancer team science that can be readily adopted by others. Read More at Cancer Discovery...

Continue reading